~~<i id='48A4F5CCFF'><strike id='48A4F5CCFF'><tt id='48A4F5CCFF'><pre id='48A4F5CCFF'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：fashion 2025-09-11 12:47:22 Page View：866

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water
Next article： Medicare proposal to cover medical devices draws a mixed reaction

leisure time

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

The aspartame in Diet Coke probably isn’t giving you cancer

NicholasHunt/GettyImagesThisessaywasoriginallypublishedonGideonMeyerowitz-Katz’sMediumblog.Aspartame

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Pfizer, Moderna say biotech, pharma drug development is a sprint

Fromlefttoright,STAT'sDamianGarde;MikaelDolsten,chiefscientificofficerofPfizerresearchanddevelopment